Quality of monitoring for metabolic effects associated with second generation antipsychotics in patients with schizophrenia on public insurance

Schizophrenia Research

Volumn 126, Issue 1-3, 2011, Pages 117-123

  Moeller, Karen E ^a,b   Rigler, Sally K ^b   Mayorga, Angela ^a,b   Nazir, Niaman ^b   Shireman, Theresa I ^b  

^a UNIVERSITY OF KANSAS   (United States)

^b UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

Antipsychotics; Diabetes; Dyslipidemia; Monitoring; Quality of care; Schizophrenia

Indexed keywords

GLUCOSE; LIPID; NEUROLEPTIC AGENT;

ADULT; ARTICLE; BLOOD GLUCOSE MONITORING; COHORT ANALYSIS; COMORBIDITY; DEMOGRAPHY; DYSLIPIDEMIA; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; HEALTH CARE QUALITY; HUMAN; INSURANCE; LABORATORY TEST; LIPID ANALYSIS; LIPID BLOOD LEVEL; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MEDICAID; METABOLIC DISORDER; OBSERVATIONAL STUDY; PATIENT MONITORING; PRIORITY JOURNAL; PUBLIC HEALTH INSURANCE; QUALITY CONTROL; RETROSPECTIVE STUDY; RURAL AREA; SCHIZOPHRENIA; URBAN AREA;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; BLOOD GLUCOSE; COHORT STUDIES; DIABETES MELLITUS; DYSLIPIDEMIAS; FEMALE; HUMANS; INSURANCE, HEALTH; LIPIDS; MALE; MASS SCREENING; METABOLIC DISEASES; MIDDLE AGED; RETROSPECTIVE STUDIES; SCHIZOPHRENIA; UNITED STATES; YOUNG ADULT;

EID: 79952007424     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2010.11.015     Document Type: Article

References (20)

1. Allison D.B., Mentore J.L., Heo M., Chandler L.P., Cappelleri J.C., Infante M.C., Weiden P.J. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am. J. Psychiatry 1999, 156(11):1686-1696.
2. American Diabetes Association (ADA) Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diab. Care 2003, 26(Suppl 1):S5-S20.
3. American Diabetes Association (ADA), American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity Consensus development conference on antipsychotic drugs and obesity and diabetes. Diab. Care 2004, 27(2):596-601.
4. American Diabetes Association (ADA), American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity Consensus development conference on antipsychotic drugs and obesity and diabetes. J. Clin. Psychiatry 2004, 65(2):267-272.
5. Barnes T.R., Paton C., Hancock E., Cavanagh M.R., Taylor D., Lelliott P. Screening for the metabolic syndrome in community psychiatric patients prescribed antipsychotics: a quality improvement programme. Acta Psychiatr. Scand. 2008, 118(1):26-33.
6. Bryden K.E., Kopala L.C. Body mass index increase of 58% associated with olanzapine. Am. J. Psychiatry 1999, 156(11):1835-1836.
7. Casey D.E., Haupt D.W., Newcomer J.W., Henderson D.C., Sernyak M.J., Davidson M., Lindenmayer J.P., Manoukian S.V., Banerji M.A., Lebovitz H.E., Hennekens C.H. Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia. J. Clin. Psychiatry 2004, 65(Suppl 7):4-18.
8. Colton C.W., Manderscheid R.W. Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states. Prev. Chron. Dis. 2006, 3(2):A42.
9. Grundy S.M., Cleeman J.I., Merz C.N., Brewer H.B., Clark L.T., Hunninghake D.B., Pasternak R.C., Smith S.C., Stone N.J. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004, 110(2):227-239.
10. Harris E.C., Barraclough B. Excess mortality of mental disorder. Br. J. Psychiatry 1998, 173:11-53.
11. Haupt D.W., Rosenblatt L.C., Kim E., Baker R.A., Whitehead R., Newcomer J.W. Prevalence and predictors of lipid and glucose monitoring in commercially insured patients treated with second-generation antipsychotic agents. Am. J. Psychiatry 2009, 166(3):345-353.
12. Ketter T.A., Haupt D.W. Perceptions of weight gain and bipolar pharmacotherapy: results of a 2005 survey of physicians in clinical practice. Curr. Med. Res. Opin. 2006, 22(12):2345-2353.
13. Lean M.E., Pajonk F.G. Patients on atypical antipsychotic drugs: another high-risk group for type 2 diabetes. Diab. Care 2003, 26(5):1597-1605.
14. McIntyre R.S., McCann S.M., Kennedy S.H. Antipsychotic metabolic effects: weight gain, diabetes mellitus, and lipid abnormalities. Can. J. Psychiatry 2001, 46(3):273-281.
15. Morrato E.H., Newcomer J.W., Allen R.R., Valuck R.J. Prevalence of baseline serum glucose and lipid testing in users of second-generation antipsychotic drugs: a retrospective, population-based study of Medicaid claims data. J. Clin. Psychiatry 2008, 69(2):316-322.
16. Morrato E.H., Newcomer J.W., Kamat S., Baser O., Harnett J., Cuffel B. Metabolic screening after the ADA's consensus statement on antipsychotic drugs and diabetes. Diab. Care 2009, 32(6):1037-1042.
17. Morrato E.H., Druss B., Hartung D.M., Valuck R.J., Allen R., Campagna E., Newcomer J.W. Metabolic testing rates in 3 state Medicaid programs after FDA warnings and ADA/APA recommendations for second-generation antipsychotic drugs. Arch. Gen. Psychiatry 2010, 67(1):17-24.
18. Newcomer J.W., Haupt D.W., Fucetola R., Melson A.K., Schweiger J.A., Cooper B.P., Selke G. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch. Gen. Psychiatry 2002, 59(4):337-345.
19. Suppes T., McElroy S.L., Hirschfeld R. Awareness of metabolic concerns and perceived impact of pharmacotherapy in patients with bipolar disorder: a survey of 500 US psychiatrists. Psychopharmacol. Bull. 2007, 40(2):22-37.
20. The National Cholesterol Education Program Executive summary of the Third Report of The National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001, 285(19):2486-2497.